Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF

被引：112
作者：
Rothermundt, M
Falkai, P
Ponath, G
Abel, S
Bürkle, H
Diedrich, M
Hetzel, G
Peters, M
Siegmund, A
Pedersen, A
Maier, W
Schramm, J
Suslow, T
Ohrmann, P
Arolt, V
机构：
[1] Univ Munster, Dept Psychiat, D-48149 Munster, Germany
[2] Univ Saarland, Dept Psychiat, Saarbrucken, Germany
[3] Univ Munster, Dept Anesthesiol & Intens Care, D-48149 Munster, Germany
[4] Univ Bonn, Dept Psychiat, D-5300 Bonn, Germany
[5] Univ Bonn, Dept Neurosurg, D-5300 Bonn, Germany
来源：
MOLECULAR PSYCHIATRY | 2004年 / 9卷 / 10期
关键词：
D O I：
10.1038/sj.mp.4001548
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：897 / 899
页数：4
相关论文
共 10 条
[1]   Tripartite synapses: glia, the unacknowledged partner [J].
Araque, A ;
Parpura, V ;
Sanzgiri, RP ;
Haydon, PG .
TRENDS IN NEUROSCIENCES, 1999, 22 (05) :208-215
[2]   S100 proteins:: Structure, functions and pathology [J].
Heizmann, CW ;
Fritz, G ;
Schäfer, BW .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2002, 7 :D1356-D1368
[3]   Increased serum S100B protein in schizophrenia: a study in medication-free patients [J].
Lara, DR ;
Gama, CS ;
Belmonte-de-Abreu, P ;
Portela, LVC ;
Goncalves, CA ;
Fonseca, M ;
Hauck, S ;
Souza, DO .
JOURNAL OF PSYCHIATRIC RESEARCH, 2001, 35 (01) :11-14
[4]   Schizophrenia as a disorder of developmentally reduced synaptic connectivity [J].
McGlashan, TH ;
Hoffman, RE .
ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (07) :637-648
[5]   Quality assurance for cerebrospinal fluid protein analysis: International consensus by an Internet-based group discussion [J].
Reiber, H ;
Thompson, EJ ;
Grimsley, G ;
Bernardi, G ;
Adam, P ;
de Almeida, SM ;
Fredman, P ;
Keir, G ;
Lammers, M ;
Liblau, R ;
Menna-Barreto, MM ;
Maria, JS ;
Seres, E ;
Sindic, CJM ;
Teelken, A ;
Trendelenburg, C ;
Trojano, M ;
van Antwerpen, MP ;
Verbeek, MM .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (03) :331-337
[6]   Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology [J].
Rothermundt, M ;
Missler, U ;
Arolt, V ;
Peters, M ;
Leadbeater, J ;
Wiesmann, M ;
Rudolf, S ;
Wandinger, KP ;
Kirchner, H .
MOLECULAR PSYCHIATRY, 2001, 6 (04) :445-449
[7]   S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia [J].
Rothermundt, M ;
Ponath, G ;
Glaser, T ;
Hetzel, G ;
Arolt, V .
NEUROPSYCHOPHARMACOLOGY, 2004, 29 (05) :1004-1011
[8]   S100B in brain damage and neurodegeneration [J].
Rothermundt, M ;
Peters, M ;
Prehn, JHM ;
Arolt, V .
MICROSCOPY RESEARCH AND TECHNIQUE, 2003, 60 (06) :614-632
[9]   Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia [J].
Schroeter, ML ;
Abdul-Khaliq, H ;
Frühauf, S ;
Höhne, R ;
Schick, G ;
Diefenbacher, A ;
Blasig, IE .
SCHIZOPHRENIA RESEARCH, 2003, 62 (03) :231-236
[10]   The reduced neuropil hypothesis: A circuit based model of schizophrenia [J].
Selemon, LD ;
Goldman-Rakic, PS .
BIOLOGICAL PSYCHIATRY, 1999, 45 (01) :17-25
1